{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:56:59Z","timestamp":1791352619412,"version":"4.3.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1038\/bjc.2016.120","type":"journal-article","created":{"date-parts":[[2016,5,3]],"date-time":"2016-05-03T20:03:40Z","timestamp":1462305820000},"page":"1199-1205","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma"],"prefix":"10.1038","volume":"114","author":[{"given":"C","family":"Le Tourneau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Dreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Kirova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J J","family":"Grob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Jouary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Dutriaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Lebb\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Mortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Saiag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M F","family":"Avril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Maubec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Bey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M","family":"Cosset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J S","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Asselain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Devun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M E","family":"Marty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Dutreix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,3]]},"reference":[{"issue":"10","key":"BFbjc2016120_CR1","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/cgt.2011.39","volume":"18","author":"N Berthault","year":"2011","unstructured":"Berthault N, Maury B, Agrario C, Herbette A, Sun JS, Peyrieras N, Dutreix M (2011) Comparison of distribution and activity of nanoparticles with short interfering DNA (Dbait) in various living systems. Cancer Gene Ther 18 (10): 695\u2013706.","journal-title":"Cancer Gene Ther"},{"issue":"10","key":"BFbjc2016120_CR2","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.neo.2014.08.008","volume":"16","author":"J Biau","year":"2014","unstructured":"Biau J, Devun F, Jdey W, Kotula E, Quanz M, Chautard E, Sayarath M, Sun JS, Verrelle P, Dutreix M (2014) A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma. Neoplasia 16 (10): 835\u2013844.","journal-title":"Neoplasia"},{"issue":"5","key":"BFbjc2016120_CR3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1097\/01.cad.0000127665.74096.93","volume":"15","author":"PA Bradbury","year":"2004","unstructured":"Bradbury PA, Middleton MR (2004) DNA repair pathways in drug resistance in melanoma. Anticancer Drugs 15 (5): 421\u2013426.","journal-title":"Anticancer Drugs"},{"issue":"1","key":"BFbjc2016120_CR4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10456-013-9385-2","volume":"17","author":"AM Das","year":"2014","unstructured":"Das AM, Seynhaeve AL, Rens JA, Vermeulen CE, Koning GA, Eggermont AM, Ten Hagen TL (2014) Differential TIMP3 expression affects tumor progression and angiogenesis in melanomas through regulation of directionally persistent endothelial cell migration. Angiogenesis 17 (1): 163\u2013177.","journal-title":"Angiogenesis"},{"issue":"3","key":"BFbjc2016120_CR5","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1148\/radiol.13130805","volume":"270","author":"F Devun","year":"2014","unstructured":"Devun F, Biau J, Huerre M, Croset A, Sun JS, Denys A, Dutreix M (2014) Colorectal cancer metastasis: the DNA repair inhibitor Dbait increases sensitivity to hyperthermia and improves efficacy of radiofrequency ablation. Radiology 270 (3): 736\u2013746.","journal-title":"Radiology"},{"issue":"3","key":"BFbjc2016120_CR6","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s00535-011-0483-x","volume":"47","author":"F Devun","year":"2012","unstructured":"Devun F, Bousquet G, Biau J, Herbette A, Roulin C, Berger F, Sun JS, Robine S, Dutreix M (2012) Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer. J Gastroenterol 47 (3): 266\u2013275.","journal-title":"J Gastroenterol"},{"issue":"9","key":"BFbjc2016120_CR7","first-page":"503","volume":"37","author":"C Fellner","year":"2012","unstructured":"Fellner C (2012) Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. P T 37 (9): 503\u2013530.","journal-title":"P T"},{"issue":"2","key":"BFbjc2016120_CR8","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","volume":"369","author":"O Hamid","year":"2013","unstructured":"Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369 (2): 134\u2013144.","journal-title":"N Engl J Med"},{"issue":"3","key":"BFbjc2016120_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/nrc2342","volume":"8","author":"T Helleday","year":"2008","unstructured":"Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA (2008) DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 8 (3): 193\u2013204.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"BFbjc2016120_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1158\/1535-7163.MCT-15-0408","volume":"15","author":"NI Herath","year":"2016","unstructured":"Herath NI, Devun F, Lienafa MC, Herbette A, Denys A, Sun JS, Dutreix M (2016) The DNA repair inhibitor DT01 as a novel therapeutic strategy for chemosensitization of colorectal liver metastasis. Mol Cancer Ther 15 (1): 15\u201322.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"BFbjc2016120_CR11","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1634\/theoncologist.2009-0237","volume":"15","author":"C Kim","year":"2010","unstructured":"Kim C, Lee CW, Kovacic L, Shah A, Klasa R, Savage KJ (2010) Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide. Oncologist 15 (7): 765\u2013771.","journal-title":"Oncologist"},{"issue":"574","key":"BFbjc2016120_CR12","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1259\/0007-1285-48-574-863","volume":"48","author":"DP Kingsley","year":"1975","unstructured":"Kingsley DP (1975) An interesting case of possible abscopal effect in malignant melanoma. Br J Radiol 48 (574): 863\u2013866.","journal-title":"Br J Radiol"},{"issue":"2","key":"BFbjc2016120_CR13","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1158\/1078-0432.CCR-11-1491","volume":"18","author":"JM Kirkwood","year":"2012","unstructured":"Kirkwood JM, Bastholt L, Robert C, Sosman J, Larkin J, Hersey P, Middleton M, Cantarini M, Zazulina V, Kemsley K, Dummer R (2012) Phase II, open-label, randomized trial of the MEK1\/2 inhibitor selumetinib as monotherapy vs temozolomide in patients with advanced melanoma. Clin Cancer Res 18 (2): 555\u2013567.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"BFbjc2016120_CR14","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1148\/radiology.164.3.3112864","volume":"164","author":"JB Konefal","year":"1987","unstructured":"Konefal JB, Emami B, Pilepich MV (1987) Malignant melanoma: analysis of dose fractionation in radiation therapy. Radiology 164 (3): 607\u2013610.","journal-title":"Radiology"},{"issue":"5","key":"BFbjc2016120_CR15","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/j.1755-148X.2008.00484.x","volume":"21","author":"S Liu","year":"2008","unstructured":"Liu S, Ren S, Howell P, Fodstad O, Riker AI (2008) Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling. Pigment Cell Melanoma Res 21 (5): 545\u2013558.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"6212","key":"BFbjc2016120_CR16","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1126\/science.1253735","volume":"346","author":"JA Lo","year":"2014","unstructured":"Lo JA, Fisher DE (2014) The melanoma revolution: from UV carcinogenesis to a new era in therapeutics. Science 346 (6212): 945\u2013949.","journal-title":"Science"},{"issue":"8","key":"BFbjc2016120_CR17","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/cncr.22988","volume":"110","author":"KR Olivier","year":"2007","unstructured":"Olivier KR, Schild SE, Morris CG, Brown PD, Markovic SN (2007) A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma. Cancer 110 (8): 1791\u20131795.","journal-title":"Cancer"},{"issue":"10","key":"BFbjc2016120_CR18","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1056\/NEJMoa1112824","volume":"366","author":"MA Postow","year":"2012","unstructured":"Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, Sedrak C, Jungbluth AA, Chua R, Yang AS, Roman RA, Rosner S, Benson B, Allison JP, Lesokhin AM, Gnjatic S, Wolchok JD (2012) Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366 (10): 925\u2013931.","journal-title":"N Engl J Med"},{"key":"BFbjc2016120_CR19","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1158\/1078-0432.CCR-08-2108","volume":"15","author":"M Quanz","year":"2009","unstructured":"Quanz M, Berthault N, Roulin C, Roy M, Herbette A, Agrario C (2009a) Small-molecule drugs mimicking DNA damage: a new strategy for sensitizing tumors to radiotherapy. Clin Cancer Res 15: 1308\u20131316.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"BFbjc2016120_CR20","doi-asserted-by":"publisher","first-page":"e6298","DOI":"10.1371\/journal.pone.0006298","volume":"4","author":"M Quanz","year":"2009","unstructured":"Quanz M, Chassoux D, Berthault N, Agrario C, Sun JS, Dutreix M (2009b) Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response. PLoS One 4 (7): e6298.","journal-title":"PLoS One"},{"issue":"1","key":"BFbjc2016120_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/09553008514551051","volume":"48","author":"IR Radford","year":"1985","unstructured":"Radford IR (1985) The level of induced DNA double-strand breakage correlates with cell killing after X-irradiation. Int J Radiat Biol Relat Stud Phys Chem Med 48 (1): 45\u201354.","journal-title":"Int J Radiat Biol Relat Stud Phys Chem Med"},{"issue":"2","key":"BFbjc2016120_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1089\/oli.2009.0180","volume":"19","author":"M Robbins","year":"2009","unstructured":"Robbins M, Judge A, MacLachlan I (2009) siRNA and innate immunity. Oligonucleotides 19 (2): 89\u2013102.","journal-title":"Oligonucleotides"},{"issue":"1","key":"BFbjc2016120_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372 (1): 30\u201339.","journal-title":"N Engl J Med"},{"issue":"3","key":"BFbjc2016120_CR24","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/0360-3016(91)90053-7","volume":"20","author":"WT Sause","year":"1991","unstructured":"Sause WT, Cooper JS, Rush S, Ago CT, Cosmatos D, Coughlin CT, JanJan N, Lipsett J (1991) Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys 20 (3): 429\u2013432.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"BFbjc2016120_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/CMR.0b013e32832ac775","volume":"19","author":"P Savoia","year":"2009","unstructured":"Savoia P, Fava P, Nardo T, Osella-Abate S, Quaglino P, Bernengo MG (2009) Skin metastases of malignant melanoma: a clinical and prognostic survey. Melanoma Res 19 (5): 321\u2013326.","journal-title":"Melanoma Res"},{"key":"BFbjc2016120_CR26","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1038\/mtna.2012.27","volume":"1","author":"A Schlegel","year":"2012","unstructured":"Schlegel A, Buhler C, Devun F, Agrario C, Urien S, Lokiec F, Sun JS, Dutreix M (2012) Pharmacokinetics and toxicity in rats and monkeys of coDbait: a therapeutic double-stranded DNA oligonucleotide conjugated to cholesterol. Mol Ther Nucleic Acids 1: e33.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"23","key":"BFbjc2016120_CR27","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15 (23): 7412\u20137420.","journal-title":"Clin Cancer Res"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2016120.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2016120","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2016120.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:32:20Z","timestamp":1684416740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2016120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["BFbjc2016120"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2016.120","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"4 February 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BD reports grants and personal fees from Roche, grants and personal fees from Bristol-Myers Squibb, grants and personal fees from GlaxoSmithKline, outside the submitted work. CL reports personal fees from Roche, GlaxoSmithKline, Merck Sharp and Dhome, Bristol-Myers Squibb outside the submitted work. FD is employee of DNA Therapeutics; JMC, JSS and MD are cofounders of DNA Therapeutics, the company which holds the patent for DT01. MEM served as a consultant for DNA Therapeutics, Oncoethics, Merck Sharp and Dhome, Pfizer and Roche laboratories. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}